Loading clinical trials...
Loading clinical trials...
In this study, the investigators propose to use mucosal impedance (MI), a minimally invasive technology, to detect mucosal damage (i.e. barrier dysfunction) based on mucosal conductivity changes in the colonic epithelium.
The intestinal epithelium functions to separate luminal contents from the interstitium. Increased intestinal permeability can represent compromise of the epithelium's integrity. Prior research has demonstrated that defects in intestinal barrier function are associated with inflammatory bowel disease (IBD) and increased intestinal permeability can be important in the maintenance of remission in IBD patients. There is currently not a convenient way to measure colonic epithelial barrier function in real time which could provide clinically relevant information .
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
Vanderbilt University Medical Center Endoscopy Laboratory
Nashville, Tennessee, United States
Start Date
November 1, 2016
Primary Completion Date
May 1, 2019
Completion Date
May 1, 2019
Last Updated
May 7, 2021
32
ACTUAL participants
mucosal impedance (MI) testing
DIAGNOSTIC_TEST
Lead Sponsor
Vanderbilt University Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06579443